Author | Geoffrey R. Oxnard, MD


Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC

April 30, 2010

ByGeoffrey R. Oxnard, MD|Vincent A. Miller, MD

Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of patients with non–small-cell lung cancer (NSCLC).